Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Middle East News Journal.
Press releases published on October 21, 2025
Day One to Report Third Quarter 2025 Financial Results Tuesday, November 4, 2025
BRISBANE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life- …
ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) Emerging as Leader in New Class of Mining Juniors
NEW YORK, Oct. 21, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands within the Dynamic Brand Portfolio@IBN ( …
Quoin Pharmaceuticals Announces U.S. FDA Grants Orphan Drug Designation for QRX003 in Netherton Syndrome
Upon Approval of NDA Quoin Will Receive Seven Years Marketing Exclusivity for QRX003 in the US Orphan Drug Designation previously granted by the European Medicines Agency in May 2025 ASHBURN, Va., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals …
Avalyn Announces Multiple Presentations at the Pulmonary Fibrosis Foundation (PFF) Summit 2025
BOSTON, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on the development of inhaled therapies for the treatment of life-threatening pulmonary diseases, today announced multiple presentations at the …
Ardelyx Announces Four Abstracts Accepted for Poster Presentations at the American Society of Nephrology’s Kidney Week
WALTHAM, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today …
XORTX Announces Pricing of US$1.1 Million Registered Direct Offering
CALGARY, Alberta, Oct. 21, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and …
Discovery Announces Resource Development Agreement with Taykwa Tagamou Nation
TORONTO, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Discovery Silver Corp. (TSX: DSV, OTCQX: DSVSF) (“Discovery” or the “Company”) today announced that the Company and Taykwa Tagamou Nation (“TTN”) have entered into a Resource Development Agreement (“RDA”). The RDA …
First American Uranium Inc. Announces Addition of Former Canadian Politician Hon. Kerry-Lynne D. Findlay and Mining Veteran Joseph A. Carrabba to Board of Directors
Vancouver, BC, Oct. 21, 2025 (GLOBE NEWSWIRE) -- First American Uranium Inc. (CSE: URM) (FSE: IOR) (OTCPK: FAUMF) (“First American”, or the “Company”) is pleased to announce the appointments of the Hon. Kerry-Lynne D. Findlay and Joseph A. Carrabba to the …
Clearmind Medicine Enrolls Last Patient for the First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
Vancouver, Canada, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to …
InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference
JENA, Germany, Oct. 21, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its participation in the Guggenheim Securities 2nd …
Mutuum Finance (MUTM) to Enable ETH Lending and Borrowing in Upcoming V1 Protocol Launch
Dubai, UAE, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Mutuum Finance (MUTM) has announced new details regarding its upcoming Version 1 (V1) protocol launch, confirming that ETH lending and borrowing will be among the first core features available on deployment. …
Hengrui Pharma and Kailera Therapeutics Announce Phase 3 HRS9531 Obesity Data Presentation at ObesityWeek® 2025
SHANGHAI and WALTHAM, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Hengrui Pharma (Hengrui), a global pharmaceutical company focused on scientific and technological innovation, and Kailera Therapeutics, Inc. (Kailera), a clinical-stage biopharmaceutical …
First Atlantic Nickel Announces Expanded 4-Kilometer Strike Length at RPM Zone from DTR Surface Sampling at Pipestone XL Nickel Alloy Project
GRAND FALLS-WINDSOR, Newfoundland and Labrador, Oct. 21, 2025 (GLOBE NEWSWIRE) -- First Atlantic Nickel Corp. (TSX-V: FAN) (OTCQB: FANCF) (FSE: P21) ("First Atlantic" or the "Company") is pleased to report that recent Davis Tube Recovery (DTR) surface …
Nxera’s Partner Cancer Research UK Presents Data from Successfully Completed Phase 1 Clinical Trial of Cancer Immunotherapy Drug HTL0039732 at ESMO
HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist with the potential to treat a wide range of cancers in combination with other immunotherapies HTL0039732, was found to be well-tolerated, confirmed target engagement and …
Notice to holders of Icelandic Depository Receipts Simplification and streamlining of Amaroq’s securities under a single ISIN
Reykjavík, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Amaroq Ltd. (“Amaroq” or the “Company”) Notice to holders of Icelandic Depository Receipts Simplification and streamlining of Amaroq’s securities under a single ISIN TORONTO, ONTARIO – 21 October 2025 – Amaroq …
Tilkynning til handhafa íslenskra heimildarskírteina Einföldun á útgáfu hlutabréfa félagsins undir einu ISIN númeri
Reykjavík, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Amaroq Ltd. (“Amaroq” eða “félagið”) Tilkynning til handhafa íslenskra heimildarskírteina Einföldun á útgáfu hlutabréfa félagsins undir einu ISIN númeri Amaroq Ltd. (AIM, TSX-V, NASDAQ Iceland: AMRQ, OTCQX: …
PIVOT-PO Phase 3 Data Show Tebipenem HBr’s Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)
Data presented at IDWeek 2025 after study stopped early for efficacy Primary endpoint met, demonstrating non-inferiority of oral tebipenem HBr compared to intravenous treatment1 Data will be shared with regulatory authorities to support regulatory filings …
XORTX Issues Correction Notice and XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency
CALGARY, Alberta, Oct. 20, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and …